Stocks-IMGN-ImmunoGen Inc

IMGN ImmunoGen Inc

4.67 0.07 (1.59%)
Delayed Prices By NASDAQ, in USD Market Closed
Invest

Overview

Prev Close4.60
Day's Range 4.49 - 4.74
52 Week Range 3.10 - 6.61
Average Volume (3M)3.64M
1-Year Return-19.77%
Beta1.3731
Market Cap1.02B
P/E Ratio
Revenue95.61M
EPS-0.8191
Dividend (Yield)0 (0%)
1 Day 1 Week 1 Month 3 Months 6 Months 1 Year 3 Years Max
Chart times in UTC
Industry Biotechnology
CEO Mark Joseph Enyedy
Employees 106

FINANCIAL SUMMARY

For the fiscal year ended 31/12/2021: ImmunoGen Inc's revenues decreased by 47.20% and amounted to 69.86M. Net income decreased by 213.94% to -139.30M. Net assets increased by 376.20% to 426.53M and EPS decreased from -0.25 to -0.68.
IMGN's Investor Relations
Income StatementBalance SheetCash Flow Statement
Quarterly
Gross Margin
98.10%
Net Profit Margin
-168.86%
Operating Margin
-204.89%
Return On Investment
-134.59%
12/21
03/22
06/22
09/22
Total Revenue
27.99M
38.08M
14.16M
15.38M
Gross Profit
N/A
37.61M
N/A
14.95M
Operating Income
-34.55M
N/A
-61.05M
-77.43M
Net Income
-37.17M
-24.15M
-62.02M
-77.76M